Summit Completes 2017 With Discuva Buy
Executive Summary
After good news on the funding front in the 2017 third quarter, UK biotech Summit Therapeutics has completed the year on a high, acquiring fellow UK biotech Discuva to add a novel antibiotic discovery platform to its expertise.
You may also be interested in...
Polyphor Proceeding With POL7080 Testing After Roche Hands Antibiotic Back
Polyphor Ltd says it will proceed alone with Phase II testing of its macrocycle antibiotic candidate POL7080 after Roche Holdings AG decided it would take too long to develop the investigational drug for treating patients with severe Pseudomonas aeruginosa infections, and so handed it back to the Swiss biotech.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.